Cargando…

Cross-sectional increase of adherence to multidisciplinary tumor board decisions

BACKGROUND: Cancer research has made great progress in the recent years. With the increasing number of options in diagnosis and therapy the implementation of tumorboards (TUBs) has become standard procedure in the treatment of cancer patients. Adherence tests on tumor board decisions are intended to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollunder, S., Herrlinger, U., Zipfel, M., Schmolders, J., Janzen, V., Thiesler, T., Güresir, E., Schröck, A., Far, F., Pietsch, T., Pantelis, D., Thomas, D., Vornholt, S., Ernstmann, N., Manser, T., Neumann, M., Funke, B., Schmidt-Wolf, I. G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162965/
https://www.ncbi.nlm.nih.gov/pubmed/30268109
http://dx.doi.org/10.1186/s12885-018-4841-4
_version_ 1783359263421235200
author Hollunder, S.
Herrlinger, U.
Zipfel, M.
Schmolders, J.
Janzen, V.
Thiesler, T.
Güresir, E.
Schröck, A.
Far, F.
Pietsch, T.
Pantelis, D.
Thomas, D.
Vornholt, S.
Ernstmann, N.
Manser, T.
Neumann, M.
Funke, B.
Schmidt-Wolf, I. G. H.
author_facet Hollunder, S.
Herrlinger, U.
Zipfel, M.
Schmolders, J.
Janzen, V.
Thiesler, T.
Güresir, E.
Schröck, A.
Far, F.
Pietsch, T.
Pantelis, D.
Thomas, D.
Vornholt, S.
Ernstmann, N.
Manser, T.
Neumann, M.
Funke, B.
Schmidt-Wolf, I. G. H.
author_sort Hollunder, S.
collection PubMed
description BACKGROUND: Cancer research has made great progress in the recent years. With the increasing number of options in diagnosis and therapy the implementation of tumorboards (TUBs) has become standard procedure in the treatment of cancer patients. Adherence tests on tumor board decisions are intended to enable quality assurance and enhancement for work in tumor boards in order to continuously optimize treatment options for cancer patients. METHODS: Subject of this study was the adherence of the recommendations made in three of 14 tumorboards, which take place weekly in the Center for Integrated Oncology (CIO) at the University Hospital Bonn. In total, therapy recommendations of 3815 patient cases were checked on their implementation. A classification into four groups has been made according to the degree of implementation. A second classification followed regarding the reasons for differences between the recommendation and the therapy which the patient actually received. RESULTS: The study showed that 80.1% of all recommendations in the three TUBs were implemented. 8.3% of all recommendations showed a deviance. Most important reasons for the deviances were patient wish (36.5%), patient death (26%) and doctoral decision, due to the patient’s comorbidities or side effects of the treatment (24.1%).Interestingly, deviance in all three tumor boards in total significantly decreased over time. CONCLUSIONS: Aim of the study was to clarify the use of tumor boards and find approaches to make them more efficient. Based on the results efficiency might be optimized by increased consideration of patients` preferences, improved presentation of patient-related data, more detailed documentation and further structuring of the tumor board meetings.
format Online
Article
Text
id pubmed-6162965
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61629652018-10-04 Cross-sectional increase of adherence to multidisciplinary tumor board decisions Hollunder, S. Herrlinger, U. Zipfel, M. Schmolders, J. Janzen, V. Thiesler, T. Güresir, E. Schröck, A. Far, F. Pietsch, T. Pantelis, D. Thomas, D. Vornholt, S. Ernstmann, N. Manser, T. Neumann, M. Funke, B. Schmidt-Wolf, I. G. H. BMC Cancer Research Article BACKGROUND: Cancer research has made great progress in the recent years. With the increasing number of options in diagnosis and therapy the implementation of tumorboards (TUBs) has become standard procedure in the treatment of cancer patients. Adherence tests on tumor board decisions are intended to enable quality assurance and enhancement for work in tumor boards in order to continuously optimize treatment options for cancer patients. METHODS: Subject of this study was the adherence of the recommendations made in three of 14 tumorboards, which take place weekly in the Center for Integrated Oncology (CIO) at the University Hospital Bonn. In total, therapy recommendations of 3815 patient cases were checked on their implementation. A classification into four groups has been made according to the degree of implementation. A second classification followed regarding the reasons for differences between the recommendation and the therapy which the patient actually received. RESULTS: The study showed that 80.1% of all recommendations in the three TUBs were implemented. 8.3% of all recommendations showed a deviance. Most important reasons for the deviances were patient wish (36.5%), patient death (26%) and doctoral decision, due to the patient’s comorbidities or side effects of the treatment (24.1%).Interestingly, deviance in all three tumor boards in total significantly decreased over time. CONCLUSIONS: Aim of the study was to clarify the use of tumor boards and find approaches to make them more efficient. Based on the results efficiency might be optimized by increased consideration of patients` preferences, improved presentation of patient-related data, more detailed documentation and further structuring of the tumor board meetings. BioMed Central 2018-09-29 /pmc/articles/PMC6162965/ /pubmed/30268109 http://dx.doi.org/10.1186/s12885-018-4841-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hollunder, S.
Herrlinger, U.
Zipfel, M.
Schmolders, J.
Janzen, V.
Thiesler, T.
Güresir, E.
Schröck, A.
Far, F.
Pietsch, T.
Pantelis, D.
Thomas, D.
Vornholt, S.
Ernstmann, N.
Manser, T.
Neumann, M.
Funke, B.
Schmidt-Wolf, I. G. H.
Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title_full Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title_fullStr Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title_full_unstemmed Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title_short Cross-sectional increase of adherence to multidisciplinary tumor board decisions
title_sort cross-sectional increase of adherence to multidisciplinary tumor board decisions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162965/
https://www.ncbi.nlm.nih.gov/pubmed/30268109
http://dx.doi.org/10.1186/s12885-018-4841-4
work_keys_str_mv AT hollunders crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT herrlingeru crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT zipfelm crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT schmoldersj crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT janzenv crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT thieslert crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT guresire crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT schrocka crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT farf crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT pietscht crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT pantelisd crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT thomasd crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT vornholts crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT ernstmannn crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT mansert crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT neumannm crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT funkeb crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions
AT schmidtwolfigh crosssectionalincreaseofadherencetomultidisciplinarytumorboarddecisions